Search Results
Your search for all items matches 34595 pages
Showing 351 - 400Addition of Brentuximab Vedotin to Lenalidomide/Rituximab in Relapsed or Refractory DLBCL
In an interim analysis of a phase III trial (ECHELON-3) reported in the Journal of Clinical Oncology, Bartlett et al found that the addition of brentuximab vedotin (BV) to lenalidomide and rituximab improved overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma...
Potential of RAD51 Testing in Tailoring Treatment Strategies in Early Breast Cancer
The RAD51 biomarker may help to tailor treatment strategies in patients with early breast cancer, according to a recent study published by Villacampa et al in Clinical Cancer Research. Background “A key objective of research focused on early-stage breast cancer is to identify biomarkers that can...
Effects of Obesity on Survival Outcomes Following Cancer Diagnosis in Pediatric Patients
Pediatric patients with cancer who have obesity at the time of diagnosis may face an elevated risk of mortality, according to a recent study published by Sassine et al in Cancer. Study Methods and Results In the retrospective study, investigators examined data from the Cancer in Young People in...
AI May Enhance Cervical Cancer Detection
Artificial intelligence (AI) could improve screening for cervical cancer, enhancing accuracy and efficiency, according to a recent review article published by Wu et al in Cancer Biology & Medicine. The report, authored by a team of researchers from the Chinese Academy of Medical Sciences and...
Therapeutic De-escalation in Breast Cancer: Can Omitting Axillary Surgery Match Survival While Improving Patient Outcomes?
Omitting axillary surgery may be an option for some patients with early-stage breast cancer, according to a study reported by Reimer et al in The New England Journal of Medicine. Previous studies, such as the SOUND trial, have indicated that avoiding an axillary procedure in patients with small...
Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality
Although lung cancer and related cancer deaths decreased in the world’s 10 most populous countries from 1990 to 2019, these positive statistics may not address trends in mortality linked to tobacco use, air pollution, and asbestos exposure, according to a recent study published by Jani et al in...
NCCN Joins International Meeting to Improve Cancer Care in the Middle East North Africa Region
The National Comprehensive Cancer Network (NCCN) announced that the organization participated in a 2-day meeting at the Middle East North Africa (MENA)–NCCN Regional Coordinating Center. Background The MENA-NCCN Regional Coordinating Center is supported by the Ministry of National Guard Health...
Medicare Advantage vs Traditional Medicare: Cost Differences in Cancer Drugs
A new study examining the use of high-cost drugs among patients with colorectal cancer and non–small cell lung cancer (NSCLC) found those insured through Medicare Advantage received less expensive cancer drugs compared to others on traditional Medicare. The findings were published by Bradley et al...
Datopotamab Deruxtecan in Advanced or Metastatic NSCLC With Actionable Genomic Alterations
As reported in the Journal of Clinical Oncology by Sands et al, the phase II TROPION-Lung05 trial showed “encouraging activity” of datopotamab deruxtecan (Dato-DXd) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) with actionable genomic alterations whose disease progressed...
Former UNMC Cancer Center Director, Kenneth H. Cowan, MD, PhD, Dies at 77
Kenneth H. Cowan, MD, PhD, served for 24 years as Director of NCI-designated cancer center at the University of Nebraska Medical Center (UNMC), now called the Nebraska Medicine Fred & Pamela Buffett Cancer Center in Omaha. Dr. Cowan died on December 15, 2024, at the age of 77 years. A native...
Novel AI Platform May Help Identify Patients Likely to Benefit Most From Clinical Trials
Researchers have demonstrated that a novel artificial intelligence (AI)-based platform could aid physicians and patients in assessing the benefit from a particular therapy being tested in a clinical trial, according to a recent study published by Orcutt et al in Nature Medicine. The AI platform may ...
ORACLE Test May Predict Survival in Early Stages of Lung Cancer
The ORACLE test may be capable of predicting lung cancer survival at the point of diagnosis more effectively than currently used clinical risk factors, according to a recent study published by Biswas et al in Nature Cancer. The findings could help physicians make more informed treatment decisions...
Long-Term Follow-up of NRG258 Trial: Adjuvant Chemoradiation vs Chemotherapy in Locally Advanced Endometrial Carcinoma
As reported in the Journal of Clinical Oncology by Matei et al, the final overall survival analysis in the long-term follow-up of the phase III NRG258 trial has shown no difference between adjuvant chemoradiation (C-RT) vs chemotherapy (CT) in patients with locally advanced endometrial carcinoma....
Adjuvant Tamoxifen Reduces 15-Year Risk of Recurrence in ‘Good Risk’ DCIS Without Radiation Therapy
Adjuvant tamoxifen was associated with a reduced risk of 15-year ipsilateral breast cancer recurrence as well as invasive ipsilateral breast cancer recurrence in patients with “good-risk” ductal carcinoma in situ (DCIS) who omitted radiation therapy after breast-conserving surgery, according to a...
Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemoradiotherapy (with or without adjuvant immunotherapy) was associated with activity in patients with locally advanced...
Adjuvant Dose-Dense vs Conventional Chemotherapy in Node-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Filho et al, 12-year follow-up of the CALBG (Alliance) C9741 trial has shown a sustained advantage of adjuvant dose-dense vs conventional chemotherapy in disease-free and overall survival in patients with node-positive breast cancer. Study Details...
Mobility Patterns and Survival Disparities in Patients With Cancer
A recent study published in Health Data Science, conducted by Fengyu Wen, PhD, MPH, of the Institute of Medical Technology at Peking University Health Science Center; Luxia Zhang, MD, MPH, of the National Institute of Health Data Science at Peking University; and colleagues, revealed significant...
Improvements in BRCA2 Testing Could Enhance Cancer Risk Assessment, Patient Care
Researchers may have advanced the understanding of genetic alterations in the BRCA2 gene, according to a recent study published by Huang et al in Nature. The findings could improve the accuracy of genetic testing and allow health-care professionals to offer more precise risk assessments and...
New Study Identifies Genes That Could Be Implicated in Glioblastoma in Adulthood
Researchers have discovered of a new type of stem cell in the brain that could lead to the development of more effective treatments in adult patients with glioblastoma, according to a recent study published by Wang et al in Nature. The finding could help explain how adult brain cells take advantage ...
Novel Tool for Predicting Response to Immunotherapy in Melanoma Under Study
A team of scientists from the United Kingdom and the United States has discovered that the activity of macrophages may prove to be useful in predicting whether or not a patient with melanoma will respond to immunotherapy. Their findings, published in JCO Oncology Advances, may help clinicians to...
Use of Denileukin Diftitox-cxdl in Relapsed or Refractory CTCL
In a registrational trial reported in the Journal of Clinical Oncology, Foss et al found that denileukin diftitox (DD)-cxdl—a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2—was active in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)....
Belzutifan Plus Cabozantinib as First-Line Treatment in Advanced Clear Cell Renal Cell Carcinoma
In a phase II trial (LITESPARK-003), reported in The Lancet Oncology, Choueiri et al found that the combination of belzutifan—a first-in-class HIF-2α inhibitor—and cabozantinib showed promising activity in the first-line treatment of patients with advanced clear cell renal cell carcinoma. Study...
OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer
For women with high-risk, BRCA-positive breast cancer, 1 year of adjuvant treatment with the PARP inhibitor olaparib following primary treatment continued to improve overall survival compared with placebo, according to the third interim analysis of the phase III OlympiA trial presented at the 2024...
Belinda Avalos, MD, Begins Term as 2025 ASH President
Belinda Avalos, MD, Professor of Medicine and a senior advisor to the President of Atrium Health Levine Cancer, will serve as president of the American Society of Hematology (ASH) for a year-long term through December 2025. Overview Dr. Avalos is a physician-scientist with a special clinical...
Benefit of Regular Physical Activity Prior to Cancer Diagnosis
Regular physical activity prior to a cancer diagnosis may be linked to a lower risk of disease progression and mortality, according to a recent study published by Mabena et al in British Journal of Sports Medicine. The findings revealed that even relatively low levels of physical activity may be...
Study Identifies Potential New Target to Overcome Breast Cancer Resistance
A new University of Cincinnati (UC) Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes. The research was recently published in the journal Cancers. Study Background Study author...
Final Overall Survival Results From SOLO3 Trial: Olaparib vs Nonplatinum Chemotherapy in Platinum-Sensitive BRCA-Mutated Relapsed Ovarian Cancer
As reported in the Journal of Clinical Oncology by Scambia et al, the final overall survival results of the phase III SOLO3 trial showed similar outcomes with olaparib vs non–platinum-based chemotherapy in patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer. In the initial report...
Nivolumab Plus AVD as Front-Line Therapy in Older Adults With Classical Hodgkin Lymphoma
In a phase I/II trial reported in the Journal of Clinical Oncology, Torka et al found that the addition of nivolumab to standard doxorubicin, vinblastine, and dacarbazine (N-AVD) was “highly effective” as front-line treatment for patients aged ≥ 60 with classical Hodgkin lymphoma. Study Details In...
Addition of Palbociclib to Standard Therapy in Metastatic Hormone Receptor–Positive, HER2-Positive Breast Cancer
Addition of the CDK4/6 inhibitor palbociclib to the current standard of care for first-line maintenance therapy after induction chemotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival in patients with hormone receptor (HR)-positive,...
Oncology Society Urges Americans to Heed Surgeon General’s Advisory on Alcohol and Cancer
On January 3, 2025, the U.S. Surgeon General’s office released a new advisory on the link between alcohol consumption and increased risk for cancer. The advisory reports alcohol use as the third leading preventable cause of cancer in the United States—after tobacco and obesity—responsible for...
Effect on Ki67 Index of High Omega-3, Low Omega-6 Diet With Fish Oil in Prostate Cancer During Active Surveillance
In a single-institution phase II trial (CAPFISH-3) reported in the Journal of Clinical Oncology, Aronson et al found that men with prostate cancer on active surveillance had a significantly reduced Ki67 index on a high omega-3, low omega-6 fatty acid diet with fish oil capsules vs no dietary...
Risk-Adapted Active Surveillance After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
In a phase II trial (RETAIN 1) reported in the Journal of Clinical Oncology, Geynisman et al found that risk-adapted active surveillance following neoadjuvant chemotherapy was associated with a high rate of metastasis-free survival in patients with muscle-invasive bladder cancer. Study Details In ...
Role of Cancer Gene in Esophageal Adenocarcinoma May Support Paradigm Shift in Predicting Disease
A genetic mutation long believed to drive the development of esophageal cancer may play a protective role early in the disease, according to a recent study published by Ganguli et al in Nature Cancer. The findings could help physicians identify which patients are at greater risk of developing...
Glucarpidase May Improve Recovery Following Methotrexate-Induced Kidney Toxicity
The drug glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy agent methotrexate, according to a recent study published by Gupta et al in Blood. Background As a result of its ability to penetrate the blood-brain barrier, methotrexate is one of the most...
Sherko Kuemmel, MD on Final Survival Results From the WSG ADAPT-HR+/HER2-Negative Chemotherapy Trial
Presented by Sherko Kuemmel, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium The WSG ADAPT trial in patients with HR-positive, HER2-negative breast cancer established that the combination of clinical risk, genomic risk, and endocrine response (Ki67 downregulation) allows...
Komal Jhaveri, MD, FACP on The Phase III EMBER Trial
At the San Antonio Breast Cancer Symposium, Komal Jhaveri, MD, FACP, presented results of the phase III EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader as monotherapy and combined with abemaciclib for patients with ER+/HER2-negative advanced breast cancer. Filmed...
Risk-Reducing Surgeries Improve Survival for Younger Patients With Breast Cancer Who Are BRCA Carriers, Study Finds
Patients with early-onset breast cancer (aged 40 or younger at diagnosis) who have BRCA1 and/or BRCA2 pathogenic or likely pathogenic variants had improved overall survival by undergoing risk-reducing surgeries, including bilateral mastectomy and/or salpingo-oophorectomy, according to data...
HRQOL With Endocrine Therapy vs Radiotherapy After Breast-Conserving Surgery in Older Women With Luminal A–Like Early Breast Cancer
As reported in The Lancet Oncology by Meattini et al, interim analysis of the phase III EUROPA trial indicated that endocrine therapy was associated with poorer health-related quality of life (HRQOL) outcomes vs radiotherapy after breast-conserving surgery in women aged ≥ 70 years with luminal...
RELATIVITY-047: Extended Analysis of Overall Survival With Nivolumab/Relatlimab vs Nivolumab in Previously Untreated Advanced Melanoma
In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma. The initial...
Psilocybin-Based Therapy May Address Mental Health Issues in Patients With Cancer, Addiction
Treatment with psilocybin may improve mental health issues among patients with cancer when accompanied by psychotherapy and could result in lasting, positive personality changes in patients with alcohol use disorder, according to two recent studies published by Petridis et al in Nature Mental...
Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases
Researchers have found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought, according to a recent study published by Holzgreve et al in JAMA Network Open. Background Prostate-specific membrane antigen–positron-emission tomography ...
Jame Abraham, MD, FACP on the PATINA Trial
Presented by Otto Metzger, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium Discussed here by Jame Abraham, MD, FACP The phase III PATINA trial showed that the addition of palbociclib to current standard-of-care first-line maintenance therapy, following induction...
Jame Abraham, MD, FACP on the Phase III ZEST Trial
Presented by Nicholas Turner, MD, PhD, on December 13, 2024 at the San Antonio Breast Cancer Symposium Discussed here by Jame Abraham, MD, FACP The ZEST phase III clinical trial was designed to evaluate the potential of the PARP inhibitor niraparib to prevent breast cancer recurrence in...
Trends in Early-Onset Colorectal Cancer
As reported in The Lancet Oncology by Sung et al, analysis of international population-based cancer registry data indicate an increase in incidence of colorectal cancer among younger persons (age < 50 years) in a majority of countries and territories examined. Study Details Colorectal cancer...
Surgeon General’s Report Calls for Cancer Warning Labels on Alcoholic Beverages
Today, Surgeon General Dr. Vivek Murthy issued an advisory citing scientific studies linking alcoholic beverages and an increased risk of at least seven cancers, including breast and colorectal cancers, and called for alcoholic beverages to carry cancer warning labels. Health warning labels on...
New Research Approaches to Metastatic Breast Cancer
Tumor cells circulating in the blood are the germ cells of breast cancer metastases. They are rare and could not be propagated in the culture dish until now. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM, and the NCT Heidelberg has now succeeded...
Novel Combination Regimen May Prevent Squamous Cell Carcinoma
A recent study by Demehri et al of Mass General Brigham investigates whether calcipotriol—a vitamin D analog—plus fluorouracil may prevent squamous cell carcinoma (SCC), with benefits lasting 5 years after treatment. This combination therapy is the first to activate specific components of the...
Addition of Nab-Paclitaxel to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancers
As reported in the Journal of Clinical Oncology by Shroff et al, the phase III SWOG S1815 trial showed that nab-paclitaxel plus gemcitabine/cisplatin (GAP regimen) did not significantly improve overall survival vs gemcitabine/cisplatin alone in newly diagnosed patients with advanced biliary tract...
Novel Prognostic Tool in Hormone Receptor–Positive, HER2-Negative, Node-Positive Breast Cancer
As reported in the Journal of Clinical Oncology, Pusztai et al developed the RSClinN+ tool—an integration of the 21-gene Oncotype DX Breast Recurrence Score (RS) test and clinicopathologic factors (tumor grade, tumor size, age)—that improved prognosis for invasive disease–free survival vs RS alone...
Maintenance Therapy After Induction With RVd With or Without Isatuximab in Transplant-Eligible Newly Diagnosed Multiple Myeloma
As reported in the Journal of Clinical Oncology by Mai et al, the German phase III GMMG-HD7 trial (Part 1) showed that the addition of isatuximab (Isa) to standard-of-care lenalidomide/bortezomib/dexamethasone (RVd) improved progression-free survival irrespective of maintenance therapy strategy in...
